186 related articles for article (PubMed ID: 9508177)
1. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Bowers DC; Aquino VM; Leavey PJ; Bash RO; Journeycake JM; Tomlinson G; Mulne AF; Haynes HJ; Winick NJ
Pediatr Blood Cancer; 2004 Jan; 42(1):93-8. PubMed ID: 14752800
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
Vo KT; Karski EE; Nasholm NM; Allen S; Hollinger F; Gustafson WC; Long-Boyle JR; Shiboski S; Matthay KK; DuBois SG
Oncotarget; 2017 Apr; 8(14):23851-23861. PubMed ID: 27793021
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
9. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.
Wells RJ; Reid JM; Ames MM; Mares WL; Krailo MD; Seibel NL; Mosher R; Reaman GH; Wiersma SR
J Pediatr Hematol Oncol; 2002 Feb; 24(2):89-93. PubMed ID: 11990712
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of combination topotecan and carboplatin in pediatric solid tumors.
Athale UH; Stewart C; Kuttesch JF; Moghrabi A; Meyer W; Pratt C; Gajjar A; Heideman RL
J Clin Oncol; 2002 Jan; 20(1):88-95. PubMed ID: 11773158
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Murren JR; Anderson S; Fedele J; Pizzorno G; Belliveau D; Zelterman D; Burtness BA; Tocino I; Flynn SD; Beidler D; Cheng YC
J Clin Oncol; 1997 Jan; 15(1):148-57. PubMed ID: 8996136
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL
J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.
Hanna NH; Gordon MS; Fife K; Sandler AB
Am J Clin Oncol; 2002 Aug; 25(4):337-9. PubMed ID: 12151959
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
[TBL] [Abstract][Full Text] [Related]
19. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
